PT2789684T - Métodos e composições para facilitar a regeneração - Google Patents
Métodos e composições para facilitar a regeneraçãoInfo
- Publication number
- PT2789684T PT2789684T PT141708024T PT14170802T PT2789684T PT 2789684 T PT2789684 T PT 2789684T PT 141708024 T PT141708024 T PT 141708024T PT 14170802 T PT14170802 T PT 14170802T PT 2789684 T PT2789684 T PT 2789684T
- Authority
- PT
- Portugal
- Prior art keywords
- compositions
- methods
- facilitating regeneration
- regeneration
- facilitating
- Prior art date
Links
- 238000000034 method Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 230000008929 regeneration Effects 0.000 title 1
- 238000011069 regeneration method Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B18/18—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B18/18—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves
- A61B18/1815—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves using microwaves
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B18/18—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves
- A61B18/20—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves using laser
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B2018/00315—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body for treatment of particular body parts
- A61B2018/00452—Skin
- A61B2018/0047—Upper parts of the skin, e.g. skin peeling or treatment of wrinkles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N7/00—Ultrasound therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N7/00—Ultrasound therapy
- A61N7/02—Localised ultrasound hyperthermia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Surgery (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Electromagnetism (AREA)
- Otolaryngology (AREA)
- Heart & Thoracic Surgery (AREA)
- Food Science & Technology (AREA)
- Physiology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Toxicology (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US5584608P | 2008-05-23 | 2008-05-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
PT2789684T true PT2789684T (pt) | 2017-02-14 |
Family
ID=41340916
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT141708024T PT2789684T (pt) | 2008-05-23 | 2009-05-22 | Métodos e composições para facilitar a regeneração |
Country Status (19)
Country | Link |
---|---|
US (4) | US20110105961A1 (pt) |
EP (3) | EP3170888A1 (pt) |
JP (6) | JP2011521009A (pt) |
KR (4) | KR101592156B1 (pt) |
CN (2) | CN102037119B (pt) |
AU (1) | AU2009248945B2 (pt) |
BR (1) | BRPI0913047A2 (pt) |
CA (1) | CA2724886C (pt) |
DK (1) | DK2789684T3 (pt) |
ES (2) | ES2616728T3 (pt) |
HK (2) | HK1150628A1 (pt) |
HU (1) | HUE031902T2 (pt) |
IL (3) | IL209513A (pt) |
MX (2) | MX342994B (pt) |
PL (1) | PL2789684T3 (pt) |
PT (1) | PT2789684T (pt) |
RU (2) | RU2640249C2 (pt) |
WO (1) | WO2009143411A2 (pt) |
ZA (1) | ZA201008209B (pt) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101592156B1 (ko) * | 2008-05-23 | 2016-02-04 | 시와 코퍼레이션 | 재생을 촉진하는 방법, 조성물 및 장치 |
WO2012047629A2 (en) | 2010-09-27 | 2012-04-12 | Siwa Corporation | Selective removal of age-modified cells for treatment of ather0sclerosis |
US8721571B2 (en) | 2010-11-22 | 2014-05-13 | Siwa Corporation | Selective removal of cells having accumulated agents |
US20140189897A1 (en) | 2011-06-21 | 2014-07-03 | Mayo Foundation For Medical Education And Research | Transgenic animals capable of being induced to delete senescent cells |
EP2790725A4 (en) | 2011-12-13 | 2015-11-04 | Buck Inst For Res On Aging | METHOD FOR IMPROVING MEDICAL THERAPIES |
WO2013158664A2 (en) | 2012-04-17 | 2013-10-24 | Kythera Biopharmaceuticals, Inc. | Use of engineered viruses to specifically kill senescent cells |
US9901081B2 (en) | 2012-08-23 | 2018-02-27 | Buck Institute For Research On Aging | Transgenic mouse for determining the role of senescent cells in cancer |
US9901080B2 (en) | 2012-08-23 | 2018-02-27 | Buck Institute For Research On Aging | Transgenic mouse having a transgene that converts a prodrug into a cytotoxic compound in senescent cells |
US10279018B2 (en) | 2012-12-03 | 2019-05-07 | Unity Biotechnology, Inc. | Immunogenic compositions for inducing an immune response for elimination of senescent cells |
CA2940123C (en) | 2013-03-24 | 2023-10-10 | Oisin Biotechnologies | Systems and methods for the targeted production of a therapeutic protein within a target cell |
US10328058B2 (en) | 2014-01-28 | 2019-06-25 | Mayo Foundation For Medical Education And Research | Treating atherosclerosis by removing senescent foam cell macrophages from atherosclerotic plaques |
US20170216286A1 (en) | 2014-01-28 | 2017-08-03 | Mayo Foundation For Medical Education And Research | Killing senescent cells and treating senescence-associated conditions using a src inhibitor and a flavonoid |
JP6688224B2 (ja) | 2014-01-28 | 2020-04-28 | バック インスティテュート フォー リサーチ オン エイジング | Mdm2を阻害する手段の投与による関節における変形性関節症の処置 |
CA2961603C (en) | 2014-09-19 | 2021-07-13 | Siwa Corporation | Anti-age antibodies for treating inflammation and auto-immune disorders |
US9993535B2 (en) | 2014-12-18 | 2018-06-12 | Siwa Corporation | Method and composition for treating sarcopenia |
US10358502B2 (en) | 2014-12-18 | 2019-07-23 | Siwa Corporation | Product and method for treating sarcopenia |
CA3000815C (en) | 2015-10-13 | 2022-11-01 | Siwa Corporation | Anti-age antibodies and methods of use thereof |
US10889634B2 (en) | 2015-10-13 | 2021-01-12 | Siwa Corporation | Anti-age antibodies and methods of use thereof |
CA3021150C (en) | 2016-02-19 | 2023-02-07 | Siwa Corporation | Method and composition for treating cancer, killing metastatic cancer cells and preventing cancer metastasis using antibody to advanced glycation end products (age) |
CN109311975A (zh) * | 2016-04-15 | 2019-02-05 | Siwa有限公司 | 用于治疗神经退行性紊乱的抗age抗体 |
WO2017222535A1 (en) | 2016-06-23 | 2017-12-28 | Siwa Corporation | Vaccines for use in treating various diseases and disorders |
US10925937B1 (en) | 2017-01-06 | 2021-02-23 | Siwa Corporation | Vaccines for use in treating juvenile disorders associated with inflammation |
US10995151B1 (en) | 2017-01-06 | 2021-05-04 | Siwa Corporation | Methods and compositions for treating disease-related cachexia |
US10961321B1 (en) | 2017-01-06 | 2021-03-30 | Siwa Corporation | Methods and compositions for treating pain associated with inflammation |
US10858449B1 (en) | 2017-01-06 | 2020-12-08 | Siwa Corporation | Methods and compositions for treating osteoarthritis |
CN110678208B (zh) | 2017-01-09 | 2024-04-05 | 奥依信生物技术公司 | 膜融合脂质纳米颗粒和制造方法以及用于产生治疗性蛋白质和用于治疗的用途 |
EP3609923A1 (en) | 2017-04-13 | 2020-02-19 | Siwa Corporation | Humanized monoclonal advanced glycation end-product antibody |
EP3619540A1 (en) | 2017-05-04 | 2020-03-11 | Siwa Corporation | Diagnostic advanced glycation end-product antibodies |
US11518801B1 (en) | 2017-12-22 | 2022-12-06 | Siwa Corporation | Methods and compositions for treating diabetes and diabetic complications |
WO2019204666A1 (en) | 2018-04-18 | 2019-10-24 | Oisin Biotechnologies, Inc. | Fusogenic lipid nanoparticles and methods for the manufacture and use thereof for the target cell-specific production of a therapeutic protein and for the treatment of a disease, condition, or disorder associated with a target cell |
WO2020023532A1 (en) | 2018-07-23 | 2020-01-30 | Siwa Corporation | Methods and compositions for treating chronic effects of radiation and chemical exposure |
US20210253739A1 (en) * | 2018-08-23 | 2021-08-19 | Siwa Corporation | Anticarboxymethyl lysine antibodies and ultrasound for removing age-modified cells |
KR20210101481A (ko) * | 2020-02-10 | 2021-08-19 | 한국과학기술연구원 | 초음파 출력부를 포함하는 노화세포 제거 장치 |
JP2023524098A (ja) | 2020-05-01 | 2023-06-08 | シワ コーポレーション | 感染症を治療する方法 |
WO2022093195A1 (en) | 2020-10-27 | 2022-05-05 | Siwa Corporation | Methods and compositions for treating osteoarthritis using anti-age antibodies or age antigens |
WO2022125776A2 (en) | 2020-12-09 | 2022-06-16 | Siwa Corporation | Methods and compositions for treating kidney diseases |
KR102650316B1 (ko) * | 2021-06-18 | 2024-03-25 | 재단법인대구경북과학기술원 | 초음파 자극이 가능한 자성 패치 및 그 제작 방법 |
WO2023023654A1 (en) | 2021-08-20 | 2023-02-23 | Siwa Corporation | Methods and compositions for treating fibrotic diseases |
WO2024102157A1 (en) | 2022-11-09 | 2024-05-16 | Siwa Corporation | Methods and compositions for treating diabetes and diabetic complications |
Family Cites Families (150)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4217344A (en) * | 1976-06-23 | 1980-08-12 | L'oreal | Compositions containing aqueous dispersions of lipid spheres |
US4900747A (en) * | 1984-03-19 | 1990-02-13 | The Rockefeller University | Method and agents for removing advanced glycosylation endproducts |
US5811075A (en) | 1984-03-19 | 1998-09-22 | The Rockefeller University | Method and agents for removing advanced glycosylation endproducts |
JP2644767B2 (ja) * | 1986-09-12 | 1997-08-25 | ザ ロックフェラー ユニバーシティ | 後生的なグリコシル化最終産物を除去する為の方法及び薬剤 |
US4917951A (en) * | 1987-07-28 | 1990-04-17 | Micro-Pak, Inc. | Lipid vesicles formed of surfactants and steroids |
US4911928A (en) * | 1987-03-13 | 1990-03-27 | Micro-Pak, Inc. | Paucilamellar lipid vesicles |
US4965288A (en) * | 1988-02-25 | 1990-10-23 | Merrell Dow Pharmaceuticals Inc. | Inhibitors of lysyl oxidase |
US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US20040208826A1 (en) * | 1990-04-02 | 2004-10-21 | Bracco International B.V. | Ultrasound contrast agents and methods of making and using them |
IN172208B (pt) * | 1990-04-02 | 1993-05-01 | Sint Sa | |
US20080063603A1 (en) * | 1990-04-02 | 2008-03-13 | Bracco International B.V. | Ultrasound contrast agents and methods of making and using them |
US6372249B1 (en) * | 1991-12-16 | 2002-04-16 | Baylor College Of Medicine | Senscent cell-derived inhibitors of DNA synthesis |
US5624804A (en) | 1991-12-20 | 1997-04-29 | The Rockefeller University | Immunochemical detection of In vivo advanced glycosylation end products |
WO1993012742A1 (fr) * | 1991-12-20 | 1993-07-08 | Technomed International | Appareil de therapie par ultrasons emettant des ondes ultrasoniques produisant des effets thermiques et des effets de cavitation |
WO1994000592A1 (en) * | 1992-06-26 | 1994-01-06 | Exocell, Inc. | Monoclonal antibodies against glycated low density lipoprotein |
US5620479A (en) * | 1992-11-13 | 1997-04-15 | The Regents Of The University Of California | Method and apparatus for thermal therapy of tumors |
US5518720A (en) * | 1992-12-30 | 1996-05-21 | Exocell, Inc. | Treatment of complications of diabetes with substances reactive with the fructosyl-lysine structure in glycated albumin |
US6387373B1 (en) * | 1993-01-15 | 2002-05-14 | Novavax, Inc. | Vaccines containing paucilsmellar lipid vesicles as immunological adjuvants |
EP0753071A1 (en) * | 1993-04-28 | 1997-01-15 | Worcester Foundation For Experimental Biology | Cell-targeted lytic pore-forming agents |
US5935927A (en) | 1994-02-03 | 1999-08-10 | The Picower Institute For Medical Research | Compositions and methods for stimulating amyloid removal in amyloidogenic diseases using advanced glycosylation endproducts |
US6410598B1 (en) | 1994-02-03 | 2002-06-25 | Michael P. Vitek | Compositions and methods for advanced glycosylation endproduct-mediated modulation of amyloidosis |
US5744318A (en) * | 1994-12-30 | 1998-04-28 | Alteon Inc. | Monoclonal antibody for the detection of advanced glycosylation endproducts in biological samples |
AU693992B2 (en) * | 1994-12-30 | 1998-07-09 | Alteon Inc. | Monoclonal antibodies specific for advanced glycosylation endproducts in biological samples |
US6176842B1 (en) * | 1995-03-08 | 2001-01-23 | Ekos Corporation | Ultrasound assembly for use with light activated drugs |
AU6907496A (en) | 1995-08-25 | 1997-03-19 | Case Western Reserve University | Process for detecting pentosidine and for assessing the biological age of a biological sample |
JP3579549B2 (ja) | 1995-10-24 | 2004-10-20 | 株式会社トクヤマ | 糖尿病または糖尿病合併症用マーカーとしての使用 |
US6090382A (en) | 1996-02-09 | 2000-07-18 | Basf Aktiengesellschaft | Human antibodies that bind human TNFα |
US5664570A (en) | 1996-02-20 | 1997-09-09 | Svc | Apparatus for applying high-intensity ultrasonic waves to a target volume within a human or animal body |
US5908925A (en) * | 1996-06-27 | 1999-06-01 | Exocell, Inc. | Genetically engineered immunoglobulins with specificity for glycated albumin |
US5984882A (en) * | 1996-08-19 | 1999-11-16 | Angiosonics Inc. | Methods for prevention and treatment of cancer and other proliferative diseases with ultrasonic energy |
US6261537B1 (en) * | 1996-10-28 | 2001-07-17 | Nycomed Imaging As | Diagnostic/therapeutic agents having microbubbles coupled to one or more vectors |
US7258857B2 (en) | 1996-11-22 | 2007-08-21 | The Trustees Of Columbia University In The City Of New York | Rage-related methods for treating inflammation |
US6245318B1 (en) * | 1997-05-27 | 2001-06-12 | Mallinckrodt Inc. | Selectively binding ultrasound contrast agents |
US7101838B2 (en) * | 1997-08-05 | 2006-09-05 | The Trustees Of Columbia University In The City Of New York | Method to prevent accelerated atherosclerosis using (sRAGE) soluble receptor for advanced glycation endproducts |
JP2001512698A (ja) * | 1997-08-08 | 2001-08-28 | ユニバーシティ オブ ワシントン | 新規な老化因子遺伝子p23の単離 |
US6380165B1 (en) * | 1997-09-19 | 2002-04-30 | The Picower Institute For Medical Research | Immunological advanced glycation endproduct crosslink |
US6896659B2 (en) * | 1998-02-06 | 2005-05-24 | Point Biomedical Corporation | Method for ultrasound triggered drug delivery using hollow microbubbles with controlled fragility |
JP4016304B2 (ja) | 1998-02-26 | 2007-12-05 | 日本油脂株式会社 | モノクローナル抗体、ハイブリッド細胞、およびモノクローナル抗体の製造方法 |
WO1999064463A1 (en) * | 1998-06-09 | 1999-12-16 | Alteon Inc. | Monoclonal antibodies specific for guanidino group-derived advanced glycosylation endproducts in biological samples |
US6753150B2 (en) | 1998-10-05 | 2004-06-22 | The Trustees Of Columbia University In The City Of New York | Method for determining whether a compound is capable of inhibiting the interaction of a peptide with rage |
ATE378418T1 (de) * | 1998-10-06 | 2007-11-15 | Univ Columbia | Extrazelluläres, neues rage-bindendes protein (en-rage) und dessen verwendungen |
US6309355B1 (en) * | 1998-12-22 | 2001-10-30 | The Regents Of The University Of Michigan | Method and assembly for performing ultrasound surgery using cavitation |
WO2000051637A1 (en) | 1999-03-02 | 2000-09-08 | Centocor, Inc. | ANTI-TNFα ANTIBODIES IN THERAPY OF ASTHMA |
US6067859A (en) | 1999-03-04 | 2000-05-30 | The Board Of Regents, The University Of Texas System | Optical stretcher |
PT1189641E (pt) | 1999-06-25 | 2009-11-04 | Genentech Inc | Anticorpos anti-erbb2 humanizados e tratamento com anticorpos anti-erbb2 |
JP2003507013A (ja) * | 1999-08-13 | 2003-02-25 | ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク | βシートフィブリルのRAGEへの結合を阻害する方法及びその結果 |
EP1219639A4 (en) | 1999-09-08 | 2009-03-25 | Toray Industries | CIPO - Patent |
US6853864B2 (en) * | 2000-02-02 | 2005-02-08 | Catholic University Of America, The | Use of electromagnetic fields in cancer and other therapies |
EP1283728A2 (en) * | 2000-05-23 | 2003-02-19 | Amersham Health AS | Contrast agents |
NO312338B1 (no) * | 2000-08-25 | 2002-04-29 | Gunnar Myhr | Anordning for selektiv celle- eller virusödeleggelse hos en levende organisme |
CN2445326Y (zh) * | 2000-10-09 | 2001-08-29 | 刘永详 | 测定被糖化蛋白的免疫分析装置 |
US6676963B1 (en) * | 2000-10-27 | 2004-01-13 | Barnes-Jewish Hospital | Ligand-targeted emulsions carrying bioactive agents |
US7481781B2 (en) * | 2000-11-17 | 2009-01-27 | Gendel Limited | Ultrasound therapy |
US6821274B2 (en) * | 2001-03-07 | 2004-11-23 | Gendel Ltd. | Ultrasound therapy for selective cell ablation |
US7347855B2 (en) | 2001-10-29 | 2008-03-25 | Ultrashape Ltd. | Non-invasive ultrasonic body contouring |
JP4727903B2 (ja) | 2001-01-03 | 2011-07-20 | ウルトラシェイプ リミティド | 非侵襲性超音波体型輪郭形成 |
ATE283481T1 (de) * | 2001-03-22 | 2004-12-15 | Hoffmann La Roche | Verfahren zum auffinden von reagenzien und festphasenkomponenten in spezifischen bindungsassays, frei von fortgeschrittenen glykosylierungsendprodukten |
US20040210042A1 (en) | 2001-07-19 | 2004-10-21 | Tsuchida Jun-Ichi | Polypeptides relating to signal transfer of advanced glycation end product receptor |
JP4012722B2 (ja) | 2001-11-22 | 2007-11-21 | 株式会社トランスジェニック | カルボキシメチル化ペプチドに対する抗体 |
MY139983A (en) | 2002-03-12 | 2009-11-30 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
AU2003254650B2 (en) * | 2002-07-24 | 2010-09-09 | Qlt, Inc. | Pyrazolylbenzothiazole derivatives and their use as therapeutic agents |
EP1575513A4 (en) | 2002-08-16 | 2007-04-04 | Wyeth Corp | COMPOSITIONS AND METHODS FOR TREATING RAGE-ASSOCIATED DISEASES |
US20070128117A1 (en) * | 2003-02-04 | 2007-06-07 | Bracco International B.V. | Ultrasound contrast agents and process for the preparation thereof |
WO2004076677A2 (en) | 2003-02-26 | 2004-09-10 | Institute For Research In Biomedicine | Monoclonal antibody production by ebv transformation of b cells |
EP1601969A2 (en) * | 2003-03-08 | 2005-12-07 | Auvation Ltd | Markers for colorectal cancer |
JP2007500521A (ja) * | 2003-07-31 | 2007-01-18 | ウッドウェルディング・アクチェンゲゼルシャフト | 傷口面に組織再生を促進する方法と装置 |
US7358226B2 (en) * | 2003-08-27 | 2008-04-15 | The Regents Of The University Of California | Ultrasonic concentration of drug delivery capsules |
WO2005070472A2 (en) * | 2004-01-20 | 2005-08-04 | Sunnybrook And Women's College Health Sciences Centre, | High frequency ultrasound imaging using contrast agents |
MXPA06009363A (es) * | 2004-02-17 | 2007-01-26 | Dynamis Therapeutics Inc | Fructosaamina 3 cinasa y la formacion de colageno y elastina. |
EP1771565B1 (en) | 2004-07-20 | 2012-09-05 | The Feinstein Institute for Medical Research | Rage protein derivatives |
NZ552128A (en) | 2004-08-03 | 2009-09-25 | Transtech Pharma Inc | Rage fusion proteins without Fc hinge region and methods of use |
GB0422525D0 (en) * | 2004-10-11 | 2004-11-10 | Luebcke Peter | Dermatological compositions and methods |
GT200600031A (es) | 2005-01-28 | 2006-08-29 | Formulacion anticuerpo anti a beta | |
WO2006094951A1 (en) * | 2005-03-03 | 2006-09-14 | Bracco Research Sa | Medical imaging system based on a targeted contrast agent |
JP2006249015A (ja) * | 2005-03-11 | 2006-09-21 | Mochida Pharmaceut Co Ltd | 細胞老化抑制剤 |
CN101120019A (zh) | 2005-04-05 | 2008-02-06 | 株式会社Jms | 对3,4-DGE来源的AGEs特异性反应的抗体 |
US20070225242A1 (en) * | 2005-06-21 | 2007-09-27 | The Board Of Trustees Of The Leland Stanford Junior University | Method and composition for treating and preventing tumor metastasis in vivo |
US20070059247A1 (en) * | 2005-08-30 | 2007-03-15 | Lindner Jonathan R | Deposit contrast agents and related methods thereof |
US20070065415A1 (en) * | 2005-09-16 | 2007-03-22 | Kleinsek Donald A | Compositions and methods for the augmentation and repair of defects in tissue |
US20070083120A1 (en) * | 2005-09-22 | 2007-04-12 | Cain Charles A | Pulsed cavitational ultrasound therapy |
US20070078290A1 (en) * | 2005-09-30 | 2007-04-05 | Esenaliev Rinat O | Ultrasound-based treatment methods for therapeutic treatment of skin and subcutaneous tissues |
US7766833B2 (en) * | 2005-11-23 | 2010-08-03 | General Electric Company | Ablation array having independently activated ablation elements |
JP4779115B2 (ja) | 2005-12-16 | 2011-09-28 | 国立大学法人東北大学 | 早期肺癌の術後予後検査方法 |
EP1988918A4 (en) * | 2006-02-22 | 2010-04-28 | Novavax Inc | ADJUVANZ AND VACCINE COMPOSITIONS |
WO2007100770A2 (en) | 2006-02-28 | 2007-09-07 | Elan Pharmaceuticals, Inc. | Methods of treating inflammatory and autoimmune diseases with natalizumab |
WO2008144753A2 (en) | 2007-05-21 | 2008-11-27 | Alder Biopharmaceuticals, Inc. | Antibodies to tnf alpha and use thereof |
WO2008154638A2 (en) | 2007-06-12 | 2008-12-18 | Board Of Regents, The University Of Texas System | Antagonists of the receptor for advanced glycation end-products (rage) |
ES2564634T3 (es) | 2007-06-14 | 2016-03-28 | Galactica Pharmaceuticals, Inc. | Proteínas de fusión de RAGE |
JP2007277263A (ja) | 2007-07-13 | 2007-10-25 | Transgenic Inc | カルボキシメチル化タンパク質に対する抗体 |
WO2009085216A2 (en) * | 2007-12-20 | 2009-07-09 | Squicor | Compositions and methods for detecting or elimninating senescent cells to diagnose or treat disease |
US7751057B2 (en) * | 2008-01-18 | 2010-07-06 | The Board Of Trustees Of The University Of Illinois | Magnetomotive optical coherence tomography |
DE102008009461A1 (de) | 2008-02-15 | 2009-08-20 | Beiersdorf Ag | Verfahren zur Reduzierung der Zeichen der Hautalterung |
EP3059248A1 (en) * | 2008-05-09 | 2016-08-24 | Abbvie Deutschland GmbH & Co. KG | Antibodies to receptor of advanced glycation end products (rage) and uses thereof |
KR101592156B1 (ko) | 2008-05-23 | 2016-02-04 | 시와 코퍼레이션 | 재생을 촉진하는 방법, 조성물 및 장치 |
JP5229473B2 (ja) * | 2008-06-04 | 2013-07-03 | 財団法人ヒューマンサイエンス振興財団 | 超音波医療装置 |
US20110319499A1 (en) | 2008-06-30 | 2011-12-29 | The Johns Hopkins University | Methods for the Detection of Advanced Glycation Endproducts and Markers for Disease |
US9155805B2 (en) | 2009-02-20 | 2015-10-13 | Perseus Proteomics Inc. | Monoclonal antibody, and use thereof |
US8343420B2 (en) * | 2009-09-17 | 2013-01-01 | Sanuwave, Inc. | Methods and devices for cleaning and sterilization with shock waves |
US20110070227A1 (en) | 2009-09-18 | 2011-03-24 | Anna-Marie Novotney-Barry | Treatment of Autoimmune and Inflammatory Diseases |
WO2011053322A1 (en) | 2009-10-30 | 2011-05-05 | University Of Arkansas For Medical Science | Use of autologous effector cells and antibodies for treatment of multiple myeloma |
WO2011101039A1 (en) | 2010-02-22 | 2011-08-25 | Universite Pierre Et Marie Curie (Paris 6) | Apparatus for the treatment of brain affections and method implementing thereof |
US9662347B2 (en) | 2010-05-11 | 2017-05-30 | Gachon University Of Industry-Academic Cooperation Foundation | Method for inhibiting the induction of cell death by inhibiting the synthesis or secretion of age-albumin in cells of the mononuclear phagocyte system |
WO2012047629A2 (en) | 2010-09-27 | 2012-04-12 | Siwa Corporation | Selective removal of age-modified cells for treatment of ather0sclerosis |
US8721571B2 (en) | 2010-11-22 | 2014-05-13 | Siwa Corporation | Selective removal of cells having accumulated agents |
WO2012135616A1 (en) | 2011-03-31 | 2012-10-04 | Siwa Corporation | Vaccination against advanced glycation end-products |
UA112434C2 (uk) | 2011-05-27 | 2016-09-12 | Ґлаксо Ґруп Лімітед | Антигензв'язувальний білок, який специфічно зв'язується з всма |
KR102068724B1 (ko) | 2011-07-10 | 2020-01-21 | 가이디드 테라피 시스템스, 엘.엘.씨. | 에너지원으로 초음파를 이용한 피부 외양을 개선하는 시스템 및 방법 |
US8954155B2 (en) | 2011-09-19 | 2015-02-10 | Biotalk Technologies Inc | Apparatus and method for rejuvenating skin |
CN103857697A (zh) | 2011-09-23 | 2014-06-11 | 伍兹堡尤利乌斯-马克西米利安斯大学 | 形成金黄色葡萄球菌表位结合位点的肽或肽的组合 |
WO2013070468A1 (en) | 2011-11-08 | 2013-05-16 | The Trustees Of The University Of Pennsylvania | Glypican-3-specific antibody and uses thereof |
KR101939401B1 (ko) | 2011-11-10 | 2019-01-16 | 가천대학교 산학협력단 | 단핵식세포계 세포의 age-알부민 합성 또는 분비 저해제를 유효성분으로 포함하는 허혈성 심장질환 예방 또는 치료용 조성물 |
KR102084806B1 (ko) | 2012-02-17 | 2020-03-04 | 시애틀 지네틱스, 인크. | 인테그린 αvβ6에 대한 항체 및 암을 치료하기 위한 그의 용도 |
TWI557112B (zh) | 2012-03-05 | 2016-11-11 | 百靈佳殷格翰國際股份有限公司 | β-分泌酶抑制劑 |
US20130288980A1 (en) | 2012-04-02 | 2013-10-31 | Buck Institute For Research On Aging | Targeting senescent and cancer cells for selective killing by interference with foxo4 |
US10379026B2 (en) | 2012-08-29 | 2019-08-13 | Inguran, Llc | Cell processing using magnetic particles |
KR101520336B1 (ko) | 2012-11-30 | 2015-05-14 | 전남대학교산학협력단 | 패혈증 비브리오균의 편모 구성성분인 플라젤린과 병원체의 항원 단백을 융합시킨 재조합 단백을 포함하는 노화 예방, 개선 또는 치료용 조성물 |
EP2742935A1 (en) | 2012-12-14 | 2014-06-18 | Tissue Med Biosciences Forschungs- und Entwicklungsgesellschaft mbH | SERF2 for the treatment of atrophy and for increasing cell growth |
BR112015021708A2 (pt) | 2013-03-06 | 2017-08-29 | Protalix Ltd | Inibidor de polipetídeo do tnfa, polinucleotídeo isolado, estrutura de expressão de ácido nucleico, célula de planta, composição farmacêutica e método de produção de um inibidor de polipeptídeo do tnfa |
US20140257262A1 (en) | 2013-03-11 | 2014-09-11 | Alexandre Carpentier | Interstitial ultrasonic disposable applicator and method for tissue thermal conformal volume ablation and monitoring the same |
AU2014249107C1 (en) | 2013-03-12 | 2018-07-19 | Molecular Templates, Inc. | CD20-binding immunotoxins for inducing cellular internalization and methods using same |
KR20170042495A (ko) | 2013-12-16 | 2017-04-19 | 제넨테크, 인크. | 펩티드모방체 화합물 및 그의 항체-약물 접합체 |
JP6793902B2 (ja) | 2013-12-20 | 2020-12-02 | ノバルティス アーゲー | 調節可能キメラ抗原受容体 |
EP3094350B1 (en) | 2014-01-15 | 2020-03-04 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Cartilage targeting agents and their use |
WO2015112835A1 (en) | 2014-01-24 | 2015-07-30 | COLE Research & Design, Inc. | Oral suction device |
JP6688224B2 (ja) | 2014-01-28 | 2020-04-28 | バック インスティテュート フォー リサーチ オン エイジング | Mdm2を阻害する手段の投与による関節における変形性関節症の処置 |
US20170216286A1 (en) | 2014-01-28 | 2017-08-03 | Mayo Foundation For Medical Education And Research | Killing senescent cells and treating senescence-associated conditions using a src inhibitor and a flavonoid |
DE102014107077B3 (de) | 2014-05-20 | 2015-08-13 | Ecs Engineered Control Systems Ag | Schaltvorrichtung |
US10238742B2 (en) | 2014-06-25 | 2019-03-26 | Yale University | Cell penetrating nucleolytic antibody based cancer therapy |
CA2961603C (en) | 2014-09-19 | 2021-07-13 | Siwa Corporation | Anti-age antibodies for treating inflammation and auto-immune disorders |
US20170240632A1 (en) | 2014-10-16 | 2017-08-24 | The Broad Institute Inc. | Compositions and methods for identifying and treating cachexia or pre-cachexia |
US10358502B2 (en) | 2014-12-18 | 2019-07-23 | Siwa Corporation | Product and method for treating sarcopenia |
US9993535B2 (en) | 2014-12-18 | 2018-06-12 | Siwa Corporation | Method and composition for treating sarcopenia |
US10889634B2 (en) | 2015-10-13 | 2021-01-12 | Siwa Corporation | Anti-age antibodies and methods of use thereof |
CA3000815C (en) | 2015-10-13 | 2022-11-01 | Siwa Corporation | Anti-age antibodies and methods of use thereof |
KR102503910B1 (ko) | 2015-11-09 | 2023-02-27 | 삼성전자주식회사 | 기립 보조 방법 및 장치 |
CA3021150C (en) | 2016-02-19 | 2023-02-07 | Siwa Corporation | Method and composition for treating cancer, killing metastatic cancer cells and preventing cancer metastasis using antibody to advanced glycation end products (age) |
US10981021B2 (en) | 2016-03-11 | 2021-04-20 | Carthera | Method for transiently disrupting a region of the blood-brain barrier of a human |
CN109311975A (zh) | 2016-04-15 | 2019-02-05 | Siwa有限公司 | 用于治疗神经退行性紊乱的抗age抗体 |
WO2017222535A1 (en) | 2016-06-23 | 2017-12-28 | Siwa Corporation | Vaccines for use in treating various diseases and disorders |
US10858449B1 (en) * | 2017-01-06 | 2020-12-08 | Siwa Corporation | Methods and compositions for treating osteoarthritis |
US10925937B1 (en) | 2017-01-06 | 2021-02-23 | Siwa Corporation | Vaccines for use in treating juvenile disorders associated with inflammation |
US10995151B1 (en) | 2017-01-06 | 2021-05-04 | Siwa Corporation | Methods and compositions for treating disease-related cachexia |
US10961321B1 (en) | 2017-01-06 | 2021-03-30 | Siwa Corporation | Methods and compositions for treating pain associated with inflammation |
EP3609923A1 (en) | 2017-04-13 | 2020-02-19 | Siwa Corporation | Humanized monoclonal advanced glycation end-product antibody |
EP3619540A1 (en) | 2017-05-04 | 2020-03-11 | Siwa Corporation | Diagnostic advanced glycation end-product antibodies |
WO2020023532A1 (en) | 2018-07-23 | 2020-01-30 | Siwa Corporation | Methods and compositions for treating chronic effects of radiation and chemical exposure |
WO2020036973A1 (en) | 2018-08-14 | 2020-02-20 | Imel Biotherapeutics, Inc. | Methods and compositions for treating mitochondrial disease or disorders and heteroplasmy |
US20210253739A1 (en) | 2018-08-23 | 2021-08-19 | Siwa Corporation | Anticarboxymethyl lysine antibodies and ultrasound for removing age-modified cells |
JP2023524098A (ja) | 2020-05-01 | 2023-06-08 | シワ コーポレーション | 感染症を治療する方法 |
WO2021247397A2 (en) | 2020-06-04 | 2021-12-09 | Siwa Corporation | Methods and compositions for enhancing the immune system |
-
2009
- 2009-05-22 KR KR1020157007520A patent/KR101592156B1/ko active IP Right Grant
- 2009-05-22 EP EP16198527.0A patent/EP3170888A1/en not_active Withdrawn
- 2009-05-22 RU RU2015114990A patent/RU2640249C2/ru active
- 2009-05-22 RU RU2010152693/10A patent/RU2553225C2/ru active
- 2009-05-22 HU HUE14170802A patent/HUE031902T2/en unknown
- 2009-05-22 EP EP14170802.4A patent/EP2789684B1/en active Active
- 2009-05-22 ES ES14170802.4T patent/ES2616728T3/es active Active
- 2009-05-22 DK DK14170802.4T patent/DK2789684T3/en active
- 2009-05-22 KR KR1020127026483A patent/KR20120127543A/ko active Application Filing
- 2009-05-22 KR KR1020137028228A patent/KR101537460B1/ko active IP Right Grant
- 2009-05-22 JP JP2011511734A patent/JP2011521009A/ja active Pending
- 2009-05-22 EP EP09751639.7A patent/EP2294178B1/en active Active
- 2009-05-22 PT PT141708024T patent/PT2789684T/pt unknown
- 2009-05-22 MX MX2014006768A patent/MX342994B/es unknown
- 2009-05-22 US US12/994,421 patent/US20110105961A1/en not_active Abandoned
- 2009-05-22 KR KR1020107026063A patent/KR20110000585A/ko not_active Application Discontinuation
- 2009-05-22 MX MX2010012473A patent/MX2010012473A/es active IP Right Grant
- 2009-05-22 PL PL14170802T patent/PL2789684T3/pl unknown
- 2009-05-22 BR BRPI0913047-0A patent/BRPI0913047A2/pt not_active Application Discontinuation
- 2009-05-22 CN CN200980118817.6A patent/CN102037119B/zh active Active
- 2009-05-22 CA CA2724886A patent/CA2724886C/en active Active
- 2009-05-22 AU AU2009248945A patent/AU2009248945B2/en active Active
- 2009-05-22 ES ES09751639.7T patent/ES2499395T3/es active Active
- 2009-05-22 WO PCT/US2009/044951 patent/WO2009143411A2/en active Application Filing
- 2009-05-22 CN CN201510303227.8A patent/CN104987416A/zh active Pending
-
2010
- 2010-11-16 ZA ZA2010/08209A patent/ZA201008209B/en unknown
- 2010-11-23 IL IL209513A patent/IL209513A/en active IP Right Grant
-
2011
- 2011-05-11 HK HK11104615.4A patent/HK1150628A1/xx unknown
- 2011-12-21 US US13/332,976 patent/US9161810B2/en active Active
-
2015
- 2015-01-23 HK HK15100739.9A patent/HK1200485A1/xx unknown
- 2015-04-03 JP JP2015076575A patent/JP2015131846A/ja active Pending
- 2015-07-30 IL IL240242A patent/IL240242A0/en unknown
- 2015-11-04 US US14/932,200 patent/US20180111982A2/en not_active Abandoned
-
2016
- 2016-05-17 JP JP2016098558A patent/JP6359051B2/ja active Active
- 2016-10-31 IL IL248652A patent/IL248652A0/en active IP Right Grant
-
2017
- 2017-04-26 JP JP2017086871A patent/JP6637465B2/ja active Active
- 2017-09-29 US US15/720,912 patent/US11261241B2/en active Active
-
2019
- 2019-12-20 JP JP2019230026A patent/JP2020050666A/ja active Pending
-
2022
- 2022-03-31 JP JP2022059633A patent/JP2022089873A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1200485A1 (en) | Methods and compositions for facilitating regeneration | |
HRP20190214T1 (hr) | Pripravci i metode za liječenje purpure | |
IL210153A0 (en) | Nutrigenomics methods and compositions | |
IL212822A0 (en) | Anti-cxcr1 compositions and methods | |
ZA201006944B (en) | Compositions and methods for preparing and using same | |
EP2308884A4 (en) | PROCESS FOR THE PREPARATION OF HETEROSUBSTITUTED ALKYLHALOHYDROSILANE AND ITS USE | |
GB0819530D0 (en) | Methods and compositions | |
IL210097A0 (en) | Compositions and methods for treating unfluenza | |
EP2229175A4 (en) | COMPOSITION AND METHOD FOR SKIN REGENERATION | |
ZA201007830B (en) | Compositions and methods for immunity | |
HK1212698A1 (zh) | 噻唑基和噁唑基異喹哪啶以及它們的使用方法 | |
EP2349519A4 (en) | COMPOSITIONS AND METHOD FOR RESOLVING OILS | |
AP2011005562A0 (en) | Phenanthrenone compounds, compositions and methods | |
GB0811250D0 (en) | Methods and compositions | |
GB0707235D0 (en) | Methods and compositions for tissue regeneration | |
GB0803464D0 (en) | Methods and compositions | |
GB0818399D0 (en) | Methods and compositions | |
GB0816534D0 (en) | Compositions and methods | |
GB0811152D0 (en) | Methods and compositions | |
GB0802079D0 (en) | Method and compositions | |
GB0806334D0 (en) | Method and composition | |
GB0817553D0 (en) | Composition and method | |
GB0816946D0 (en) | Composition and method |